Drug Profile
Research programme: cancer therapy - Erimos
Alternative Names: EM-6110aLatest Information Update: 20 Sep 2011
Price :
$50
*
At a glance
- Originator Erimos Pharmaceuticals
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Phase Unknown Solid tumours